5-Bromo-2-Chlorobenzoic Acid CAS 21739-92-4 Dapagliflozin Intermediate Factory

Short Description:

Chemical Name: 5-Bromo-2-Chlorobenzoic Acid 

CAS: 21739-92-4

Assay: ≥99.0% 

Appearance: Off-White to Light Yellow Powder

Intermediate of Dapagliflozin (CAS: 461432-26-8) in the treatment of type II diabetes

High Quality, Commercial Production

Inquiry: alvin@ruifuchem.com


Product Detail

Related Products

Product Tags

Description:

Manufacturer Supply, High Purity, Commercial Production
Dapagliflozin (CAS: 461432-26-8) Related Intermediates:
5-Bromo-2-Chlorobenzoic Acid CAS 21739-92-4
5-Bromo-2-Chloro-4'-Ethoxydiphenylmethane CAS 461432-23-5
2,3,4,6-Tetrakis-O-Trimethylsilyl-D-Gluconolactone CAS 32384-65-9

Chemical Properties:

Chemical Name 5-Bromo-2-Chlorobenzoic Acid
Synonyms 2-Chloro-5-Bromobenzoic Acid
CAS Number 21739-92-4
CAT Number RF-PI439
Stock Status In Stock, Production Scale Up to Tons
Molecular Formula C7H4BrClO2 
Molecular Weight 235.46
Melting Point 154.0 to 156.0℃ (lit.)
Brand Ruifu Chemical

Specifications:

Item Specifications
Appearance Off-White to Light Yellow Powder
Assay ≥99.0%
Water (K.F) ≤0.50%
Residue on Ignition ≤0.30%
2-Chlorobenzoic Acid ≤0.30%
2-Chloro-3-Bromobenzoic Acid ≤0.30%
Total Impurities ≤1.0%
Test Standard Enterprise Standard
Usage Intermediate of Dapagliflozin (CAS: 461432-26-8), type II diabetes

Package & Storage:

Package: Bottle, Aluminium foil bag, 25kg/Cardboard Drum, or according to customer's requirement.

Storage Condition: Store in sealed containers at cool and dry place; Protect from light and moisture.

Advantages:

1

FAQ:

Application:

5-Bromo-2-Chlorobenzoic Acid (CAS: 21739-92-4) is used as a starting material in the synthesis of Dapagliflozin (CAS: 461432-26-8), a selective sodium-glucose cotransporter-2 inhibitor that reduces renal glucose reabsorption and is used to treat patients with type II diabetes. Dapagliflozin is a potent and selective SGLT-2(SLC5A2 )inhibitor with EC50 of 1.1 nM. It has good permeability across Caco-2 cell membranes and is a substrate for P-glycoprotein (P-gp). Dapagliflozin was approved in 2012 by FDA. 

  • Write your message here and send it to us